Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Significance: There is a growing interest in the gut- and hindbrain-produced hormone glucagon-like peptide 1 (GLP-1), and GLP-1–targeting drugs are in clinical trials for treatment of obesity, and already in the clinic for treatment of type 2 diabetes. Therefore, the implications of information arising from our study are clinically relevant and considerable. GLP-1 receptor stimulation decreases feeding and body weight likely via the CNS, effects of unquestioned scientific and clinical importance, considering the alarming rates of obesity. Despite this, there is scarce information about the mediators and mechanisms behind the effects of GLP-1. In this study, we found surprising evidence that two cytokines, interleukin-6 and interleukin-1, mediate antiobesity effects of GLP-1 receptor stimulation at the level of the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Interleukin-6-deficient mice develop mature-onset obesity
Wallenius, V., Wallenius, K., Ahrén, B., Rudling, M., Carlsten, H., Dickson, S. L., Ohlsson, C., & Jansson, J.-O. (2002) · Nature Medicine · doi:10.1038/nm0102-75 · Cited by 1,213 · cited 4×
“(1996) Central administration of GLP-1-(7-36) amide in-”
InfluentialSelf-citationLarsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 5×
“(1996) Central administration of GLP-1-(7-36) amide in-”
InfluentialGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 6×
“This effect is likely exerted via GLP-1Rs in the CNS, but the GLP-1R mechanism of action remains to be elucidated.”
InfluentialKanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · cited 10×
“Two-way ANOVA revealed no interaction, and post hoc Tukey test after a one-way ANOVA [F (3,33) = 12.”
InfluentialInterleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance
Matthews, V. B., Allen, T. L., Risis, S., Chan, M. H. S., Henstridge, D. C., Watson, N., Zaffino, L. A., Babb, J. R., Boon, J., Meikle, P. J., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1865-y · Cited by 334 · cited 4×
“(1996) Central administration of GLP-1-(7-36) amide in-”
InfluentialDifferences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor
McFarland-Mancini, M. M., Funk, H. M., Paluch, A. M., Zhou, M., Giridhar, P. V., Mercer, C. A., Kozma, S. C., & Drew, A. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901929 · Cited by 249
Cited by
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
GLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290
Self-citationGonzalez-Gil, A. M., & Elizondo-Montemayor, L. (2020) · Nutrients · doi:10.3390/nu12061899 · Cited by 278
“AT: adipose tissue, ANGPTL4: Angiopoietin-like 4; BAIBA: β-Aminoisobutyric acid; BAT: Brown (and beige) adipose tissue; EE: Energy expenditure; ER: Endoplasmic reticulum; FAO: Fatty acid oxidation; FI: Food intake; FGF21: Fibroblast growth factor 21; GH: Growth hormone; GLP-1: Glucagon-like peptide 1; IL-1Ra: Interleu…”
InfluentialThe Versatile Tanycyte: A Hypothalamic Integrator of Reproduction and Energy Metabolism
Prevot, V., Dehouck, B., Sharif, A., Ciofi, P., Giacobini, P., & Clasadonte, J. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00235 · Cited by 278
Metadata
- Authors
- Shirazi, R., Palsdottir, V., Collander, J., Anesten, F., Vogel, H., Langlet, F., Jaschke, A., Schürmann, A., Prévot, V., Shao, R., Jansson, J.-O., & Skibicka, K. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-09-18
- Volume
- 110
- Issue
- 40
- Pages
- 16199-16204
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2001484259
- Cited by
- 137
- References
- 11
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. https://app.cochat.ai/papers/10.1073/pnas.1306799110
- The paper
- Shirazi, R., Palsdottir, V., Collander, J., Anesten, F., Vogel, H., Langlet, F., Jaschke, A., Schürmann, A., Prévot, V., Shao, R., Jansson, J.-O., & Skibicka, K. P. (2013). Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1306799110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.